author: Evan Hughes
2023-06-22
Pan Macmillan
The Hard Sell : Crime & Punishment at an Opioid Startup | Evan Hughes
OMR
7.5
Available in store
Check availability in store
Please enable your browser location services in order for us to help you get personalized store listing based on your current location. Alternatively, you may proceed to choose store from list or search for your favorite store.
Store finder
Soon to be the Netflix film Pain Hustlers starring Emily Blunt
‘A pacey crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading The Hard Sell is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me I’m wrong.' - Patrick Radden Keefe, The New York Times
In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market.
Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the government’s fight to hold the drug industry accountable in the spread of addictive opioids.
With colourful characters and true suspense, The Hard Sell lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream – in the doctor’s office . . .
‘A pacey crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading The Hard Sell is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me I’m wrong.' - Patrick Radden Keefe, The New York Times
In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market.
Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the government’s fight to hold the drug industry accountable in the spread of addictive opioids.
With colourful characters and true suspense, The Hard Sell lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream – in the doctor’s office . . .
7.5
100.0
200.0
OMR
7.5
Soon to be the Netflix film Pain Hustlers starring Emily Blunt
‘A pacey crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading The Hard Sell is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me I’m wrong.' - Patrick Radden Keefe, The New York Times
In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market.
Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the government’s fight to hold the drug industry accountable in the spread of addictive opioids.
With colourful characters and true suspense, The Hard Sell lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream – in the doctor’s office . . .
‘A pacey crime caper set against the backdrop of the opioid crisis . . . When I tell you that reading The Hard Sell is like watching a Scorsese film, you will assume I am exaggerating. Pick it up and tell me I’m wrong.' - Patrick Radden Keefe, The New York Times
In the early 2000s, John Kapoor had already amassed a small fortune in pharmaceuticals when he founded Insys Therapeutics. A boom time for painkillers, he had developed a novel formulation of fentanyl, the most potent opioid on the market.
Kapoor, a brilliant scientist with relentless business instincts, was eager to make the most of his innovation. But there was a problem: the drug was approved only for cancer patients in dire condition. So he recruited an avaricious team, who employed a variety of deceptive techniques, from falsifying patient records to deceiving insurance companies. Insys became a Wall Street sensation. That is, until insiders reached their breaking point and blew the whistle, sparking a sprawling investigation in the government’s fight to hold the drug industry accountable in the spread of addictive opioids.
With colourful characters and true suspense, The Hard Sell lays bare the pharma playbook. Evan Hughes offers a bracing look not just at Insys, but at how opioids are sold at the point they first enter the national bloodstream – in the doctor’s office . . .
View full description
View less description
publisher
Pan MacmillanSpecifications
Books
Number of Pages
288
Publication Date
2023-06-22
View more specifications
View less specifications
Customers